Localized Optical Coherence Tomography Precursors of Macular Atrophy and Fibrotic Scar in the Comparison of Age-Related Macular Degeneration Treatments Trials.
Aged
Aged, 80 and over
Angiogenesis Inhibitors
/ administration & dosage
Cicatrix
/ diagnosis
Cross-Sectional Studies
Female
Fluorescein Angiography
/ methods
Fundus Oculi
Humans
Intravitreal Injections
Macular Degeneration
/ complications
Male
Middle Aged
Tomography, Optical Coherence
/ methods
Vascular Endothelial Growth Factor A
/ antagonists & inhibitors
Visual Acuity
Journal
American journal of ophthalmology
ISSN: 1879-1891
Titre abrégé: Am J Ophthalmol
Pays: United States
ID NLM: 0370500
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
06
07
2020
revised:
04
09
2020
accepted:
08
11
2020
pubmed:
23
11
2020
medline:
27
4
2021
entrez:
22
11
2020
Statut:
ppublish
Résumé
To identify precursors of macular atrophy (MA) and of fibrotic scar (FS) in eyes treated with anti-vascular endothelial growth factor through pixel-mapping analysis of baseline optical coherence tomography (OCT). Design: Cross-sectional analysis. Multicenter clinical trial. 68 eyes from the Comparison of Age-Related Macular Degeneration Treatments Trials. Treatment with anti-vascular endothelial growth factor agents. The percentage of MA or FS pixels with each OCT feature at baseline, and the odds ratio for baseline pixels with an OCT feature to develop MA or FS. Retinal pigment epithelium atrophy and photoreceptor loss on OCT were highly predictive of MA at that location at years 2 and 5 (P < .0001), but accounted for only 22.5% of the ensuing atrophy at year 2 and less at year 5. Among pixels of MA at year 2, 78% were preceded by thick drusen, 54% by subretinal macular neovascularization (MNV), and 22.5% by no detectable OCT features. MNV, subretinal hyperreflective material, pigment epithelial detachment, intraretinal fluid, and sub-retinal pigment epithelium fluid were predictive of FS at that location (P values <.05). More than 75% of the pixels of FS at years 2 and 5 were preceded by pixels of baseline MNV. Most pixels of FS were preceded by components of neovascularization. Although one-quarter of MA was accounted for by pre-existing evidence of atrophy on OCT alone, the development of MA in areas of thick drusen, areas with and without subretinal MNV lesion, and areas without detectable OCT precursors argues that the development of MA is multifactorial and may follow, in part, a non-neovascular pathway.
Identifiants
pubmed: 33221285
pii: S0002-9394(20)30630-9
doi: 10.1016/j.ajo.2020.11.002
pmc: PMC7979472
mid: NIHMS1661162
pii:
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Vascular Endothelial Growth Factor A
0
Types de publication
Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
338-347Subventions
Organisme : NEI NIH HHS
ID : U10 EY023530
Pays : United States
Organisme : NEI NIH HHS
ID : U10 EY017825
Pays : United States
Organisme : NEI NIH HHS
ID : U10 EY017826
Pays : United States
Organisme : NEI NIH HHS
ID : U10 EY017828
Pays : United States
Organisme : NEI NIH HHS
ID : U10 EY017823
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Références
Ophthalmology. 2012 Jul;119(7):1388-98
pubmed: 22555112
Ophthalmology. 2018 Apr;125(4):537-548
pubmed: 29103793
Ophthalmol Retina. 2020 Mar;4(3):238-248
pubmed: 31753808
Ophthalmology. 2012 Dec;119(12):2549-57
pubmed: 22939114
Ophthalmology. 2016 Apr;123(4):865-75
pubmed: 26783095
JAMA Ophthalmol. 2020 Jul 1;138(7):740-747
pubmed: 32379287
Ophthalmology. 2018 Jul;125(7):1037-1046
pubmed: 29454660
Transl Vis Sci Technol. 2020 Jul 07;9(8):8
pubmed: 32855855
N Engl J Med. 2011 May 19;364(20):1897-908
pubmed: 21526923
Ophthalmology. 2013 Sep;120(9):1860-70
pubmed: 23642377
Prog Retin Eye Res. 2016 Jan;50:1-24
pubmed: 26307399
Ophthalmology. 2017 Dec;124(12):1764-1777
pubmed: 28847641
Ophthalmology. 2014 Oct;121(10):1956-65
pubmed: 24835760
Ophthalmology. 2010 Mar;117(3):489-99
pubmed: 20079925
Saudi J Ophthalmol. 2014 Apr;28(2):129-33
pubmed: 24843306
JAMA Ophthalmol. 2014 Aug;132(8):915-21
pubmed: 24875610
Ophthalmology. 2014 Jan;121(1):162-172
pubmed: 23993787
Ophthalmology. 2017 Jan;124(1):97-104
pubmed: 28079023
Arch Ophthalmol. 2005 Nov;123(11):1570-4
pubmed: 16286620
Ophthalmology. 2018 Jun;125(6):878-886
pubmed: 29477692
Ophthalmology. 2016 Aug;123(8):1751-1761
pubmed: 27156698
Invest Ophthalmol Vis Sci. 2012 Jan 05;53(1):53-61
pubmed: 22039246
Ophthalmology. 2015 Jan;122(1):153-61
pubmed: 25283060
Ophthalmology. 2015 Sep;122(9):1846-53.e5
pubmed: 26143666
Ophthalmology. 2019 Feb;126(2):252-260
pubmed: 30189282
Ophthalmol Retina. 2018 Oct;2(10):1021-1027
pubmed: 30506012
Ophthalmology. 2013 Nov;120(11):2292-9
pubmed: 23642856
Retina. 2016 Dec;36(12):2250-2264
pubmed: 27552292
Am J Ophthalmol. 2018 Aug;192:84-90
pubmed: 29763612
Ophthalmol Retina. 2018 May;2(5):481-493
pubmed: 31047330
Ophthalmology. 2014 Mar;121(3):656-66
pubmed: 24314839
Ophthalmology. 2014 Jan;121(1):150-161
pubmed: 24084496
Ophthalmol Retina. 2019 Apr;3(4):316-325
pubmed: 31014683
Ophthalmology. 2019 Jan;126(1):75-86
pubmed: 30301555